

Supplementary Materials:

Evaluating the Impact of the COVID-19 Pandemic on New Cancer Diagnoses and Oncology Care in Manitoba

Kathleen M. Decker, Pascal Lambert, Allison Feely, Oliver Bucher, Julian O. Kim, Pamela Hebbard, Maclean Thiessen, Tunji Fatoye, Marshall Pitz, Rashmi Koul, and Piotr Czaykowski

Table S1. Linear regression results.

			Estimate (95% Confidence Interval)	p-Value
Cancer diagnoses	Intercept		543.50 (509.62–577.37)	<0.001
	COVID-19		-1946.94 (-3211.06– -682.81)	0.003
	Time		0.94 (0.41–1.47)	0.001
	Month	'	6.24 (-49.20–61.69)	
		"	59.24 (0.35–118.14)	
		'''	-87.40 (-143.11– -31.69)	
		''''	57.87 (9.28–106.47)	0.003
		'''''	-53.19 (-131.65–25.27)	
		''''''	-1.22 (-41.59–39.15)	
	COVID-19:Time		28.27 (9.27–47.26)	0.004
Pathology reports	Intercept		2753.21 (2579.25–2927.18)	<0.001
	COVID-19		-7548.30 (-11233.57– -3863.03)	<0.001
	Time		3.89 (1.14–6.64)	0.006
	Month	'	141.04 (-135.09–417.17)	
		"	561.53 (254.00–869.06)	
		'''	-355.44 (-641.46– -69.42)	
		''''	487.20 (241.25–733.16)	<0.001
		'''''	109.76 (-300.74–524.27)	
		''''''	161.57 (-40.28–363.41)	
	COVID-19:Time		107.84 (53.69–161.98)	<0.001
Surgery	Intercept		1216.39 (1142.11–1290.68)	<0.001
	COVID-19		-739033.58 (-1548491.14–70423.98)	0.073
	Time	'	12.97 (-101.34–127.28)	
		"	59.38 (-32.33–151.08)	0.416
	Month	'	133.31 (16.91–249.70)	
		"	252.81 (127.72–377.90)	
		'''	-237.36 (-351.52– -123.19)	
		''''	445.91 (346.89–544.92)	<0.001
		'''''	-11.15 (-170.98–148.68)	
		''''''	70.80 (-11.46–153.05)	
Intravenous chemotherapy	COVID-19:Time	'	1237521.19 (-121931.90–2596974.28)	<0.001
		"	406433.82 (-36855.86–849723.50)	
	Intercept		1724.45 (1616.55–1832.35)	<0.001
	COVID-19		13.80 (-153.91–181.50)	0.870
	Time	'	108.85 (-17.16–234.86)	
		"	-87.46 (-215.45–40.53)	
		'''	-81.84 (-381.84–218.17)	0.325
		''''	1.14 (-246.19–248.47)	
	Month	'	64.30 (-82.13–210.72)	
		"	-49.26 (-130.39–31.88)	0.308
Radiotherapy treatment (first)	Intercept		338.68 (310.72–366.64)	<0.001

	COVID-19		-15.47 (-54.16–23.23)	0.428
	Time	'	9.87 (-19.08–38.81)	
		''	22.58 (-6.91–52.07)	0.024
		'''	3.91 (-65.06–72.88)	
		''''	42.89 (-14.24–100.03)	
	Month	'	-38.00 (-74.59– -1.41)	
		''	40.13 (2.36–77.90)	
		'''	-57.04 (-93.63– -20.45)	<0.001
		''''	56.00 (24.52–87.47)	
		'''''	-32.10 (-82.38–18.19)	
		''''''	-52.31 (-78.43– -26.18)	
Radiotherapy fractions	Intercept		3880.59 (3607.31–4153.88)	<0.001
	COVID-19		-563.19 (-816.57– -309.81)	<0.001
	Time		0.95 (-3.49–5.38)	0.671
	Month	'	76.12 (-368.47–520.71)	
		''	788.62 (327.16–1250.08)	
		'''	-59.70 (-501.93–382.53)	0.002
		''''	611.19 (228.08–994.30)	
		'''''	292.19 (-321.76–906.15)	
		''''''	-108.16 (-425.12–208.81)	
Urgent cancer care clinic visits	Intercept		200.67 (188.38–212.97)	<0.001
	COVID-19		-32.94 (-45.64– -20.24)	<0.001
	Time		-0.32 (-0.54– -0.10)	0.006
	Month	'	12.52 (-2.83–27.87)	
		''	-1.20 (-26.23–23.84)	0.193
		'''	-7.86 (-19.04–3.32)	
In-person visits	Intercept		9249.00 (8283.53–10214.48)	<0.001
	COVID-19		-5606.68 (-6701.30– -4512.06)	<0.001
	Time		65.47 (-8.51–139.44)	0.079
	Month	'	2244.09 (1101.43–3386.75)	
		''	59.47 (-1724.81–1843.74)	0.006
		'''	-28.30 (-791.86–735.25)	
All visits	Intercept		9464.62 (8624.16–10305.08)	<0.001
	COVID-19		-72.25 (-983.14–838.65)	0.868
	Time		66.37 (4.92–127.82)	0.036
	Month	'	5.28 (-1212.12–1222.69)	
		''	1218.44 (-1.46–2438.34)	
		'''	-863.17 (-2205.27–478.94)	0.061
		''''	1729.38 (664.35–2794.40)	
		'''''	225.08 (-1690.60–2140.76)	
		''''''	-336.50 (-1251.96–578.96)	

Abbreviations: ', splines.

Table S2. Ratios and 95% confidence intervals (CI) between predicted and expected values.

Outcome	Average	Ratio (95% CI)		
		Apr 2020	Sep 2020	Dec 2020
Cancer diagnoses*		0.77 (0.67–0.87)	1.00 (0.90–1.11)	
Pathology reports*		0.79 (0.70–0.88)		1.07 (0.98–1.16)
Surgery*		0.57 (0.45–0.70)	0.99 (0.88–1.11)	
IV chemotherapy	1.01 (0.91–1.11)			
RT treatment (first)	0.96 (0.85–1.06)			
RT fractions	0.87 (0.81–0.93)			
Urgent Cancer Care clinic (UCC) visits	0.82 (0.75–0.89)			
In-person visits	0.48 (0.38–0.58)			
All visits	0.99 (0.91–1.08)			

Abbreviations: CI, confidence interval; RT, radiotherapy; IV, intravenous.

* Significant COVID-19 by time interaction.